GPR155 Inhibitors

GPR155 inhibitors primarily target signaling pathways or cellular processes associated with G protein-coupled receptors (GPCRs). Several of these chemicals aim at the core components of GPCR signaling. Pertussis Toxin and GDP-β-S hinder Gα subunits of the G protein complex, a foundational step in many GPCR signaling cascades. By targeting these components, these inhibitors can interrupt GPR155's ability to activate its associated intracellular pathways. Similarly, NF449, focusing on the Gαs subunit, offers a nuanced approach to impede GPCR activity. On a broader scale, U73122 disrupts the GPCR-signaling landscape by inhibiting phospholipase C (PLC), thereby reducing the generation of key secondary messengers like inositol trisphosphate (IP3) and diacylglycerol (DAG).

Moving downstream in the signaling process, protein kinases play a pivotal role in amplifying and relaying the signals initiated by GPCRs. Compounds like H-89, GF 109203X, and Go 6983 have been identified as inhibitors of protein kinases A and C (PKA and PKC). Their influence on these kinases can halt the processes initiated by GPCRs, including GPR155. Additionally, the impact of targeting other cellular proteins linked to GPCR signaling is highlighted by compounds such as ML141, which inhibits the small GTPase Cdc42, and Manumycin A and Y-27632, which target Ras and ROCK, respectively.